Rapport Therapeutics Reports $40.2 Million Q3 Loss and Pipeline Update
The company reported a $40.2 million net loss for the third quarter of 2026, versus $26.9 million a year earlier, as research and development spending increased. It ended September with $395.0 million in cash, cash equivalents and short-term investments.
Story updates
12:41:52 PM UTC
SquawkNews
Rapport Therapeutics reported no revenue in the third quarter of 2026 and a net loss of $40.2 million, compared with a $26.9 million loss in the prior-year quarter. Diluted EPS was $(0.84), versus $(0.71) a year earlier.Financial HighlightsBusiness HighlightsOriginal SEC Filing: Rapport Therapeutic…
Rapport Therapeutics reported a third-quarter 2026 net loss of $40.2 million, compared with $26.9 million a year earlier, as research and development spending increased. The company ended September with $395.0 million in cash, cash equivalents and short-term investments, and reported estimated liqu…